The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment (LAMISIII)

JW Pharmaceutical

Status: Unknown

Conditions: Hypercholesterolemia

Treatments: Drug: Pitavastatin 4mg

Study type: Observational

Funder types: Industry

Identifiers

NCT04270344

JW-PTVV-01

Details and patient eligibility

About

Prospective Observation study to identify the rate of MACE in AMI with Livalo V(Pitavastatin/Valsartan) for 12 month in Korea

Full description

Following subjects with AMI event within 1 month will be assessed MACE event for 1year

• Essential hypertension or heart failure
• Idiopathic hypercholesterolemia (heterogeneous familial and non-familial hypercholesterolemia, Fredrickson classification type IIa)
• Mixed-type hypercholesterolemia (Fredrickson classification type IIb) with acute myocardial infarction (STEMI, NSTEMI),

Enrollment: 905 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• idiopathic hypercholesterolemia (heterogeneous familial and non-familial, Fredrickson type IIa) or mixed-type (Fredrickson type IIb) with AMI (STEMI, NSTEMI), including essential hypertension or heart failure
• diagnosed AMI (STEMI, NSTEMI) 1 months ago
• more than 19 years old and more than 2 years of life expectancy at screening
• informed consent

Exclusion criteria

• cardiogenic shock or corresponding clinical events
• contraindicated to the IP
• unsuitable to this study judged by investigators